It has been reported that intratumoral specific CD8+ T cell biomarkers can determine the prognosis and immunoevasive outcomes in ccRCC patients, which is a probable explanation for why ccRCC tumors progress despite a robust CD8+ T cell infiltration (23, 50, 51). This evidence concerns the gene CD8A and nonpapillary renal cell carcinoma.